Tumors after Renal Transplantation

Schmidt, Rainer; Stippel, Dirk L.; Schmitz‐Rixen, T.; Pollok, M.

doi:10.1159/000282871

Cited by 12 publications

(3 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…2,[14][15] In addition, chronic immunosuppression may cause impaired immune surveillance and may prevent the eradication of precancerous changes. 2,[16][17][18] Therefore, immunosuppressive treatment in kidney transplant recipients is an important risk factor for developing skin cancer.…”

Section: Discussionmentioning

confidence: 99%

“…The incidence of nonmelanoma skin cancer may be greater in patients who receive cyclosporine than azathioprine or tacrolimus, 13,[18][19][20] but some studies have shown no significant difference in the incidence of skin cancer between patients who received azathioprine or cyclosporine therapy. 1,8,[21][22][23] In the present study, different combinations of immunosuppressive therapies were given to kidney transplant recipients, and there were no significant differences in histologic subtypes of tumors, time from transplant to skin cancer diagnosis, or prognosis between patients having different immunosuppressive treatment.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Untitled

Tepeoğlu

Ayva²,

Atılgan³

et al. 2014

Exp Clin Transplant

View full text Add to dashboard Cite

Objectives: Solid-organ transplant recipients have a high risk of developing nonmelanoma skin cancers. This study sought to determine the incidence of skin cancer and identify possible risk factors for skin cancer in kidney transplant recipients. Materials and Methods: Nonmelanoma skin cancer was diagnosed and confirmed with histology in 33 of 1275 kidney transplant recipients (2.6%). Demographic and clinical findings were reviewed retrospectively. Results: Nonmelanoma skin cancers included squamous cell carcinoma in 10 patients (30%), basal cell carcinoma in 9 patients (27%), Kaposi sarcoma in 9 patients (27%), squamous cell carcinoma in situ in 3 patients (9%), and cutaneous lymphoma in 2 patients (6%). The ratio of squamous cell carcinoma to basal cell carcinoma was 1.1:1. The mean time from transplant to skin cancer diagnosis was 65 ± 55 months (range, 0-180 mo). Immunosuppressive therapy was based on cyclosporine in 22 patients (67%), tacrolimus in 8 patients (24%), and combination therapy (cyclosporine and azathioprine) in 3 patients (9%). Conclusions: Nonmelanoma skin cancer is an important clinical problem in kidney transplant recipients. Interventions that may benefit kidney transplant recipients may include intensive patient education, protection against sun exposure, and dermatologic screening programs.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Untitled

Tepeoğlu

Ayva²,

Atılgan³

et al. 2014

Exp Clin Transplant

View full text Add to dashboard Cite

show abstract

“…Nevertheless, in the renal transplant population, a close follow-up at regular intervals with ultrasound and urine cytology is mandatory [5].…”

Section: Discussionmentioning

confidence: 99%

Transitional Cell Carcinoma Involving the Ureterovesical Part of a Transplanted Ureter

Kmetec¹,

Kaplan-Pavlovčič²,

Ovčak

2003

Urol Int

View full text Add to dashboard Cite

Ureterovesical malignancy in the renal transplant recipient is an infrequent occurrence. We report a woman with a cadaver kidney recipient, transplanted 10 years ago, with transitional-cell carcinoma at the ureterovesical part of the transplanted ureter invading the bladder muscle around the orifice. Though aggressive surgery and chemotherapy of such patients is proposed, most patients die after an average of 16–17 months. In our patient we have done partial ureter and bladder resection in order to preserve kidney graft and bladder. We continued immunosuppressive treatment. The patient has survived 16 months and is symptom free. Our case suggests that nonaggressive operative treatment without chemotherapy in selected patients may provide comparable survival to patients with aggressive treatment, but with better quality of life.

show abstract

Skin Cancer in the Organ Transplant Patient

Berg¹,

Stasko²

2005

Surgery of the Skin

View full text Add to dashboard Cite

Tumors after Renal Transplantation

Cited by 12 publications

References 20 publications

Untitled

Untitled

Transitional Cell Carcinoma Involving the Ureterovesical Part of a Transplanted Ureter

Skin Cancer in the Organ Transplant Patient

Contact Info

Product

Resources

About